Mode
Text Size
Log in / Sign up

Meta-analysis identifies prognostic factors for recurrent VTE and bleeding in 96 753 adult cancer patientsCertain cancer types and health factors raise risk of blood clots or bleeding in adults with cancer and VTE

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider ECOG status and cancer type when stratifying VTE and bleeding risk in cancer patients.

This meta-analysis examined prognostic factors for recurrent VTE or anticoagulant-related bleeding within a cohort of 96 753 adult patients with cancer and VTE. The authors synthesized data to identify variables associated with adverse outcomes, noting that the evidence reflects associations rather than causality. The study encompasses a wide range of patient characteristics to inform risk stratification.

The analysis found that a history of VTE was associated with an adjusted hazard ratio (aHR) of 1.50 (95% CI 1.08-2.09) for recurrent VTE. Poorer performance status also increased risk, with an aHR of 1.81 (95% CI 1.34-2.46) for ECOG >0 and 2.44 (95% CI 1.55-3.84) for ECOG >1. Specific malignancies showed varying risks, including pancreas cancer (aHR 3.20, 95% CI 2.06-4.96) and hepatobiliary cancer (aHR 2.37, 95% CI 1.70-3.30). Conversely, recent surgery (aHR 0.56, 95% CI 0.40-0.76) and breast cancer (aHR 0.43, 95% CI 0.23-0.81) were associated with decreased risk of recurrent VTE.

For anticoagulant-related bleeding, a history of bleeding carried an aHR of 2.41 (95% CI 1.50-3.88). Advanced cancer (aHR 1.60, 95% CI 1.29-1.97), brain cancer (aHR 2.25, 95% CI 1.64-3.09), and gastrointestinal system cancer (aHR 1.74, 95% CI 1.44-2.11) were linked to higher bleeding risk. The authors note that adverse events, discontinuations, and tolerability were not reported. These prognostic factors should be considered as part of risk stratification frameworks for anticoagulation management in patients with cancer and VTE.

This large review analyzed data from 96,753 adult patients with cancer who also had venous thromboembolism (VTE). The goal was to identify which factors predict a higher risk of having another blood clot or experiencing bleeding while on blood thinners. The researchers looked at the patient's cancer type, overall health status, and medical history.

The analysis showed that having a history of VTE, poor overall health, or advanced cancer increased the risk of a recurrent clot. Specific cancers like pancreatic, hepatobiliary, and lung cancer were linked to higher risks. Interestingly, recent surgery or having breast cancer was associated with a lower risk of recurrent clots.

For bleeding risks, a history of bleeding, poor health, and certain cancers like brain or gastrointestinal cancers increased the chance of bleeding while on anticoagulants. These findings help doctors better understand who is at higher risk. This information should be used to improve risk assessment tools for managing blood thinners in this patient group.

What this means for you:
Certain cancers and health factors are linked to higher risks of recurrent clots or bleeding in adults with cancer and VTE.

Study Details

Study typeMeta analysis
Sample sizen = 96
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BACKGROUND AND AIMS: Patients with cancer and venous thromboembolism (VTE) have a high risk of recurrent VTE and anticoagulant-related bleeding. This study aimed to identify prognostic factors for these complications. METHODS: A systematic review was performed for randomized trials and cohort studies evaluating prognostic factors for recurrent VTE or anticoagulant-related bleeding in adult patients with cancer and VTE. Adjusted hazard ratios (aHRs) for factors were pooled using random-effects meta-analysis. The certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation approach. RESULTS: Thirty-three studies (n = 96 753) were included in the meta-analyses. Factors with high certainty of association with increased risk of recurrent VTE included a previous history of VTE [aHR 1.50 (95% CI 1.08-2.09)], Eastern Cooperative Oncology Group (ECOG) performance status >0 [1.81 (1.34-2.46)] or >1 [2.44 (1.55-3.84)], advanced cancer [1.38 (1.15-1.65)], and specific cancer sites including lung [1.78 (1.29-2.46)], hepatobiliary [2.37 (1.70-3.30)], pancreas [3.20 (2.06-4.96)], and genitourinary [1.38 (1.14-1.67)]. Conversely, recent surgery [aHR 0.56 (95% CI 0.40-0.76)] and breast cancer [0.43 (0.23-0.81)] had a high certainty of association with a decreased risk. Factors with a high certainty of association with an increased risk of anticoagulant-related bleeding included a history of bleeding [aHR 2.41 (95% CI 1.50-3.88)], ECOG performance status ≥2 [2.10 (1.48-2.99)], advanced cancer [1.60 (1.29-1.97)], and cancers of the brain [2.25 (1.64-3.09)], gastrointestinal system [1.74 (1.44-2.11)], genitourinary system [1.90 (1.48-2.45)], and prostate [1.72 (1.26-2.34)]. CONCLUSIONS: The prognostic factors identified in this meta-analysis should be considered as part of risk stratification frameworks for anticoagulation management in patients with cancer and VTE.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.